Urine test found to be extremely accurate at detecting aggressive prostate cancer with few false negatives.

Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus.

The multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.

Multi-institution analysis identifies a new chromosomal abnormality linked to enzalutamide resistance.

Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.

Antiandrogen treatment is associated with heart and neurological problems and didn’t increase survival for this group of men, a U-M analysis finds.